CGON (STOCKS)
CG Oncology, Inc. Common stock
$53.630000
+0.540000 (+1.02%)
Prev close: $53.090000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Arthur Kuan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,563.20M
- Employees
- 113
- P/E (TTM)
- -26.99
- P/B (TTM)
- 6.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $2.17M |
| Benefits Costs and Expenses | $153.66M |
| Costs And Expenses | $153.66M |
| Nonoperating Income/Loss | $28.64M |
| Operating Expenses | $182.30M |
| Research and Development | $113.48M |
| Other Operating Expenses | $68.81M |
| Operating Income/Loss | -$180.12M |
| Income/Loss From Continuing Operations After Tax | -$151.48M |
| Income/Loss From Continuing Operations Before Tax | -$151.48M |
| Net Income/Loss | -$151.48M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$151.48M |
| Net Income/Loss Available To Common Stockholders, Basic | -$151.48M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.05 |
| Diluted Earnings Per Share | -$2.05 |
| Basic Average Shares | 78,569,098 |
| Diluted Average Shares | 78,569,098 |
| Assets | $729.91M |
| Current Assets | $695.79M |
| Accounts Receivable | $515.00K |
| Inventory | $1.50M |
| Other Current Assets | $693.77M |
| Noncurrent Assets | $34.12M |
| Fixed Assets | $15.33M |
| Other Non-current Assets | $18.79M |
| Liabilities | $42.27M |
| Current Liabilities | $30.53M |
| Accounts Payable | $9.19M |
| Other Current Liabilities | $21.34M |
| Noncurrent Liabilities | $11.74M |
| Equity | $687.64M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $687.64M |
| Liabilities And Equity | $729.91M |
| Net Cash Flow From Operating Activities | -$116.79M |
| Net Cash Flow From Operating Activities, Continuing | -$116.79M |
| Net Cash Flow From Investing Activities | -$159.41M |
| Net Cash Flow From Investing Activities, Continuing | -$159.41M |
| Net Cash Flow From Financing Activities | $277.94M |
| Net Cash Flow From Financing Activities, Continuing | $277.94M |
| Net Cash Flow | $1.73M |
| Net Cash Flow, Continuing | $1.73M |
| Comprehensive Income/Loss | -$151.48M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$151.48M |
| Other Comprehensive Income/Loss | $0.00 |